Funding announcement
First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray
ENA Respiratory has begun a Phase 2a influenza-challenge trial in the UK of its INNA-051 antiviral nasal spray; the article also recalls its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.